Literature DB >> 14739339

Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis.

Evelyn A Kurt-Jones1, Melvin Chan, Shenghua Zhou, Jennifer Wang, George Reed, Roderick Bronson, Michelle M Arnold, David M Knipe, Robert W Finberg.   

Abstract

Human neonates infected with herpes simplex virus 1 (HSV-1) develop one of three distinct patterns of infection: (i) infection limited to the skin, eye or mouth; (ii) infection of the CNS; or (iii) disseminated infection. The disseminated form usually involves the liver, adrenal gland, and lung, and resembles the clinical picture of bacterial sepsis. This spectrum of symptoms in HSV-1-infected neonates suggests that inflammatory cytokines play a significant role in the pathogenesis of the disease. Recent studies suggest that the Toll-like receptors (TLRs) may play an important role in the induction of inflammatory cytokines in response to viruses. TLRs are mammalian homologues of Toll, a Drosophila protein that is essential for host defense against infection. Engagement of TLRs by bacterial, viral, or fungal components leads to the production and release of cytokines and other antimicrobial products. Here, we demonstrate that TLR2 mediates the inflammatory cytokine response to HSV-1 by using both transfected cell lines and knockout mice. Studies of infected mice revealed that HSV-1 induced a blunted cytokine response in TLR2(-/-) mice. Brain levels of monocyte chemoattractant protein 1 chemokine were significantly lower in TLR2(-/-) mice than in either wild-type or TLR4(-/-) mice. TLR2(-/-) mice had reduced mortality compared with wild-type mice. The differences between TLR2(-/-) mice and both wild-type and TLR4(-/-) mice in the induction of monocyte chemoattractant protein 1, brain inflammation, or mortality could not be accounted for on the basis of virus levels. Thus, these studies suggest the TLR2-mediated cytokine response to HSV-1 is detrimental to the host.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14739339      PMCID: PMC337050          DOI: 10.1073/pnas.0308057100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

Review 1.  The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products.

Authors:  A Bowie; L A O'Neill
Journal:  J Leukoc Biol       Date:  2000-04       Impact factor: 4.962

2.  Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components.

Authors:  O Takeuchi; K Hoshino; T Kawai; H Sanjo; H Takada; T Ogawa; K Takeda; S Akira
Journal:  Immunity       Date:  1999-10       Impact factor: 31.745

Review 3.  The Toll/interleukin-1 receptor domain: a molecular switch for inflammation and host defence.

Authors:  L O'Neill
Journal:  Biochem Soc Trans       Date:  2000-10       Impact factor: 5.407

4.  The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors.

Authors:  A Ozinsky; D M Underhill; J D Fontenot; A M Hajjar; K D Smith; C B Wilson; L Schroeder; A Aderem
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

5.  Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products.

Authors:  E Lien; T J Sellati; A Yoshimura; T H Flo; G Rawadi; R W Finberg; J D Carroll; T Espevik; R R Ingalls; J D Radolf; D T Golenbock
Journal:  J Biol Chem       Date:  1999-11-19       Impact factor: 5.157

6.  Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection.

Authors:  O Takeuchi; K Hoshino; S Akira
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

7.  Role of toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF enhances TLR2 expression and TLR2-mediated interleukin 8 responses in neutrophils.

Authors:  Evelyn A Kurt-Jones; Leisa Mandell; Constance Whitney; Alison Padgett; Kerri Gosselin; Peter E Newburger; Robert W Finberg
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

8.  Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins.

Authors:  Osamu Takeuchi; Shintaro Sato; Takao Horiuchi; Katsuaki Hoshino; Kiyoshi Takeda; Zhongyun Dong; Robert L Modlin; Shizuo Akira
Journal:  J Immunol       Date:  2002-07-01       Impact factor: 5.422

9.  Cutting edge: impaired Toll-like receptor expression and function in aging.

Authors:  Mary Renshaw; Julie Rockwell; Carrie Engleman; Andrew Gewirtz; Jacqueline Katz; Suryaprakash Sambhara
Journal:  J Immunol       Date:  2002-11-01       Impact factor: 5.422

10.  Intranasal herpes simplex virus type 2 inoculation causes a profound thymidine kinase dependent cerebral inflammatory response in the mouse hindbrain.

Authors:  Guy Boivin; Zoé Coulombe; Serge Rivest
Journal:  Eur J Neurosci       Date:  2002-07       Impact factor: 3.386

View more
  253 in total

1.  Corilagin Protects Against HSV1 Encephalitis Through Inhibiting the TLR2 Signaling Pathways In Vivo and In Vitro.

Authors:  Yuan-Jin Guo; Tao Luo; Fei Wu; Huan Liu; Hua-Rong Li; Yuan-Wu Mei; Shu-Ling Zhang; Jun-Yan Tao; Ji-Hua Dong; Yuan Fang; Lei Zhao
Journal:  Mol Neurobiol       Date:  2014-11-04       Impact factor: 5.590

Review 2.  Innate sensing of viruses by toll-like receptors.

Authors:  Karl W Boehme; Teresa Compton
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

3.  Identification of an important immunological difference between virulent varicella-zoster virus and its avirulent vaccine: viral disruption of dendritic cell instruction.

Authors:  Cindy Gutzeit; Martin J Raftery; Matthias Peiser; Karsten B Tischer; Martina Ulrich; Melanie Eberhardt; Eggert Stockfleth; Thomas Giese; Andreas Sauerbrei; Craig T Morita; Günther Schönrich
Journal:  J Immunol       Date:  2010-06-04       Impact factor: 5.422

4.  Activation of plasmacytoid dendritic cells by Kaposi's sarcoma-associated herpesvirus.

Authors:  John A West; Sean M Gregory; Vijay Sivaraman; Lishan Su; Blossom Damania
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

5.  Commensal bacteria lipoteichoic acid increases skin mast cell antimicrobial activity against vaccinia viruses.

Authors:  Zhenping Wang; Daniel T MacLeod; Anna Di Nardo
Journal:  J Immunol       Date:  2012-07-06       Impact factor: 5.422

6.  An innate antiviral pathway acting before interferons at epithelial surfaces.

Authors:  Marie B Iversen; Line S Reinert; Martin K Thomsen; Ieva Bagdonaite; Ramya Nandakumar; Natalia Cheshenko; Thaneas Prabakaran; Sergey Y Vakhrushev; Malgosha Krzyzowska; Sine K Kratholm; Fernando Ruiz-Perez; Steen V Petersen; Stanislas Goriely; Bo Martin Bibby; Kristina Eriksson; Jürgen Ruland; Allan R Thomsen; Betsy C Herold; Hans H Wandall; Sebastian Frische; Christian K Holm; Søren R Paludan
Journal:  Nat Immunol       Date:  2015-11-30       Impact factor: 25.606

7.  Efficient replication by herpes simplex virus type 1 involves activation of the IkappaB kinase-IkappaB-p65 pathway.

Authors:  D Gregory; D Hargett; D Holmes; E Money; S L Bachenheimer
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 8.  Recent advances on viral manipulation of NF-κB signaling pathway.

Authors:  Jun Zhao; Shanping He; Arlet Minassian; Junhua Li; Pinghui Feng
Journal:  Curr Opin Virol       Date:  2015-09-15       Impact factor: 7.090

9.  A promiscuous lipid-binding protein diversifies the subcellular sites of toll-like receptor signal transduction.

Authors:  Kevin S Bonham; Megan H Orzalli; Kachiko Hayashi; Amaya I Wolf; Christoph Glanemann; Wolfgang Weninger; Akiko Iwasaki; David M Knipe; Jonathan C Kagan
Journal:  Cell       Date:  2014-02-13       Impact factor: 41.582

10.  HSV ICP0 recruits USP7 to modulate TLR-mediated innate response.

Authors:  Sandrine Daubeuf; Divyendu Singh; Yaohong Tan; Hongiu Liu; Howard J Federoff; William J Bowers; Khaled Tolba
Journal:  Blood       Date:  2008-10-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.